Progress in First-Line Treatment of <i>ROS1</i> Fusion-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer From TRIDENT-1 Study

ZHONG Yu-ling; WANG Jing-yi; WU Lin

doi:10.12019/j.issn.1671-5144.202408004

ZHONG Yu-ling, WANG Jing-yi, WU Lin. Progress in First-Line Treatment of ROS1 Fusion-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer From TRIDENT-1 Study[J]. Journal of Evidence-Based Medicine, 2024, 24(4): 216-221. DOI: 10.12019/j.issn.1671-5144.202408004

Citation:

ZHONG Yu-ling, WANG Jing-yi, WU Lin. Progress in First-Line Treatment of ROS1 Fusion-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer From TRIDENT-1 Study[J]. Journal of Evidence-Based Medicine, 2024, 24(4): 216-221. DOI: 10.12019/j.issn.1671-5144.202408004

Citation:

ZHONG Yu-ling, WANG Jing-yi, WU Lin. Progress in First-Line Treatment of ROS1 Fusion-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer From TRIDENT-1 Study[J]. Journal of Evidence-Based Medicine, 2024, 24(4): 216-221. DOI: 10.12019/j.issn.1671-5144.202408004

Progress in First-Line Treatment of ROS1 Fusion-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer From TRIDENT-1 Study

Graphical Abstract

Abstract

FullText(HTML)

References (20)

Progress in First-Line Treatment of ROS1 Fusion-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer From TRIDENT-1 Study

Catalog

Export File

Citation

Format

Content